Approximately 1% of the general population has a condition on the bipolar spectrum,[1] and of this, up to 40% of people living with the condition are also struggling with substance use disorder (SUD).[2]
This huge statistical overrepresentation highlights how commonly these conditions co-occur and also prompts a deeper exploration into the relationship between bipolar disorder (BPD) and substance misuse. Understanding this connection is essential, as it influences treatment approaches, patient outcomes, and the overall trajectory of both conditions.
The Cycle of Self-Medication
Out of all of the mental health conditions, people with bipolar disorder have the second highest likelihood of a co-occurring SUD, topped only by antisocial personality disorder.[3] It also appears that there is a gender imbalance when it comes to substance use – men with bipolar are, in general, more likely to have a co-occurring SUD;[4] however, within the subsets of bipolar disorder, women with mania have significantly higher odds ratios (OR) of any drug misuse, tranquiliser misuse, cocaine and opioid use disorders. In terms of substances commonly used, alcohol is the highest percentage at 42%, followed by cannabis at 20% and other illegal drugs at 17%.
The journey through the cycle of self-medication, the intricacies of dual diagnosis, and the promising avenues of integrated treatment models offer a comprehensive view of the challenges and opportunities where these conditions overlap.
For people with bipolar disorder, using drugs and alcohol often represents an attempt to find stability amidst their fluctuating emotions, and they can often find themselves self-medicating to try and dull the sharp edges of their mood swings or ignite a spark during their depressive lows. This self-medication comes with a high price. The immediate relief is fleeting, often leading to more tolerance, addiction and, paradoxically, intensifying the very symptoms people are seeking to escape. The pursuit of a momentary reprieve can lead to more frequent and severe mood episodes, including both mania and depression, complicating the clinical picture and making effective treatment all the more challenging.[5]
Genetic and Environmental Contributions
A complex interplay of genetic and environmental factors influences the development of bipolar disorder and the propensity towards substance use disorder. These components do not act in isolation but interact in ways that increase the vulnerability to both conditions.
Genetic Factors
Studies indicate that bipolar disorder has a significant genetic component, with heritability estimates ranging from 60-80%.[6] This suggests that individuals with a family history of bipolar disorder are at an increased risk of developing the condition themselves. Similarly, substance use disorders have been linked to genetic factors, with certain genetic markers increasing the susceptibility to addiction.[7] The overlap in genetic predispositions for both conditions highlights a shared biological vulnerability that can precipitate the co-occurrence of bipolar disorder and SUD.
Environmental Factors
Similarly, environmental triggers play a key role in the onset and progression of BPD and SUD. High-stress events, trauma, and exposure to substance use at an early age are significant environmental factors that can trigger the onset of these conditions.[8] For people genetically predisposed to bipolar disorder, environmental stressors can act as a catalyst, accelerating the emergence of symptoms or contributing to the development of substance use as a coping mechanism.
Diagnostic Challenges
The crossover between bipolar disorder and substance use disorder presents significant diagnostic challenges for healthcare professionals. The overlapping symptoms of both conditions can blur the clinical picture, making it difficult to distinguish between substance-induced mood episodes and those stemming from bipolar disorder itself. This is compounded by the fact that substance use can both mimic and mask the symptoms of bipolar disorder, leading to potential misdiagnosis or delayed treatment.[9]
One of the primary hurdles in diagnosing co-occurring BPD and SUD is the tendency for substance use to induce mood episodes that closely resemble those of bipolar disorder. For example, stimulant use can trigger manic-like symptoms, while withdrawal from substances often mirrors depressive episodes, with some researchers even suggesting that alcohol withdrawal, in particular, can trigger bipolar episodes.[10] [11] This similarity can lead to confusion, with substance-induced symptoms potentially being mistaken for a primary mood disorder.
Moreover, as previously discussed, people with bipolar disorder may turn to substance use as a form of self-medication, complicating the task of identifying the root cause of mood disturbances. Therefore, a history of substance use and psychiatric symptoms must be thoroughly evaluated to discern the primary issue from secondary conditions.
When working with diagnostic challenges, a comprehensive evaluation that includes a detailed medical history, psychiatric assessment, and, when possible, input from family members or close contacts is essential. This approach allows clinicians to piece together the complex puzzle of symptoms, behaviours, and substance use patterns, which allows for accurate diagnosis and effective treatment.
Preventive Measures and Early Intervention
When working with dual diagnosis, preventive measures and early intervention are critical components when mitigating the risk and severity of these conditions. Recognising the signs early and implementing strategies to prevent the onset or escalation of substance misuse can significantly alter the trajectory for people at risk.
Preventive Measures
Education plays a pivotal role in prevention, particularly for people with a known risk of bipolar disorder. By understanding the potential for substance use as a form of self-medication, people and their families can be more vigilant when looking for signs of substance misuse. Schools, healthcare providers, and community programmes can offer resources and education on the risks associated with SUD, especially targeting demographics at higher risk due to environmental factors.
Early Intervention
Early intervention is essential when signs of bipolar disorder or substance use disorder begin to appear, as screening for symptoms of BPD in people presenting with substance use issues can facilitate timely diagnosis and treatment. Similarly, monitoring individuals diagnosed with bipolar disorder for signs of SUD can lead to early intervention and prevent dependency due to self-medication escalating into addiction.
Incorporating a dual screening approach in routine healthcare assessments can also help identify individuals who may not seek help independently, and offering support programmes that address stress management, positive coping skills, and healthy lifestyle choices can provide alternative options for managing symptoms.
.
Begin Your Journey to Wellness with Assured Healthcare and Wellness
Navigating the complexities of a dual diagnosis can be challenging, but you don’t have to do it alone. At Assured Healthcare and Wellness, we specialise in providing personalised, home-based treatment plans tailored to your unique needs.
If you or a loved one are struggling with bipolar disorder and addiction, take the first step towards recovery and reach out today to learn how our at-home treatment approach can support you as you navigate the path to wellness. We’re here to help you every step of the way.
Sources:
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3486639/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2094705/
- Ibid
- https://pubmed.ncbi.nlm.nih.gov/24677651/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2811144/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3966627/
- https://nida.nih.gov/news-events/news-releases/2023/03/new-nih-study-reveals-shared-genetic-markers-underlying-substance-use-disorders
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751794/
- https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2021.660432/full
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851027
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683827/